Clinical Trials Logo

Clinical Trial Summary

This randomized, open-label, prospective, parallel-group controlled clinical study that aims to explore the natural history of COVID-19 illness and the safety of KB109, a novel glycan, plus SSC versus SSC alone and measures of health in outpatients with mild-to-moderate COVID-19.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04414124
Study type Interventional
Source Kaleido Biosciences
Contact
Status Completed
Phase N/A
Start date August 2, 2020
Completion date February 2, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05157139 - Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease Phase 2/Phase 3
Completed NCT04486482 - A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function N/A